- Published on
KembaraXtra- Medicine – Adrenal Insufficiency
Adrenal insufficiency refers to inadequate production of adrenal corticosteroids. It most classically results from partial or complete destruction of the adrenal cortex causing primary adrenal failure (Addison disease), in which cortisol deficiency is typically accompanied by impaired mineralocorticoid (aldosterone) production. In contrast, secondary cortisol deficiency results from pituitary (or hypothalamic) dysfunction leading to reduced ACTH stimulation of the adrenal glands, causing low cortisol but usually preserved aldosterone secretion, since aldosterone is mainly regulated by the renin–angiotensin system. Adrenal insufficiency can present gradually with nonspecific symptoms, and a high index of suspicion is required because up to about half of patients may first present with an acute adrenal crisis.
Adrenal insufficiency is relatively uncommon, with a prevalence of 10–15 per 100,000 persons, and occurs more often in females than males with an approximately 2:1 ratio. Clinical presentation may be insidious and includes generalized weakness, chronic fatigue, malaise, anorexia, weight loss, nausea, vomiting, abdominal discomfort, and postural dizziness. Hyperpigmentation of the skin and mucous membranes is a hallmark of primary adrenal insufficiency due to elevated ACTH and related melanocyte-stimulating activity; it is most prominent in palmar creases, buccal mucosa, pressure points (elbows, knees, knuckles), perianal mucosa, scars, and around the areolae. Hypotension and orthostasis are common. Women may have amenorrhea and loss of axillary hair due to adrenal androgen deficiency. Laboratory abnormalities often include hyponatremia, hyperkalemia (mainly in primary disease), hypoglycemia, and prerenal azotemia (elevated BUN/creatinine ratio). Additional findings can include mild normocytic anemia, neutropenia, lymphocytosis, eosinophilia, metabolic acidosis, and occasional hypercalcemia; severe dehydration can sometimes mask hyponatremia and anemia.
The most common cause of primary adrenal insufficiency is autoimmune adrenalitis, accounting for about 80% of cases. Other important causes include tuberculosis (historically significant, still relevant in some settings), metastatic or infiltrative malignancy (including lymphoma), adrenal hemorrhage (associated with anticoagulation, trauma, coagulopathies, pregnancy, or sepsis), adrenal infarction (e.g., antiphospholipid syndrome, thrombosis, arteritis), infections in immunocompromised states such as AIDS (with CMV adrenalitis), and genetic or syndromic causes including autoimmune polyglandular syndromes types 1 and 2, X-linked adrenoleukodystrophy, and congenital adrenal hyperplasia. Additional infiltrative etiologies include sarcoidosis, amyloidosis, hemochromatosis, vasculitides such as granulomatosis with polyangiitis, postoperative adrenal loss, and fungal infections such as histoplasmosis and candidiasis. Secondary adrenal insufficiency is usually due to pituitary disease, pituitary surgery or radiation, infiltrative pituitary disorders, or suppression of the hypothalamic–pituitary–adrenal axis following chronic exogenous glucocorticoid therapy.
Because symptoms overlap with many disorders, the differential diagnosis includes sepsis, hypovolemic shock, acute abdomen, depression, anorexia nervosa, chronic infection, gastrointestinal malignancy, myopathies, salt-losing nephritis, hemochromatosis, and in older adults “apathetic hyperthyroidism.” Diagnostic evaluation typically begins with assessment of cortisol production using an early morning (around 8 A.M.) serum cortisol. A cortisol level <3 mcg />L is strongly consistent with cortisol deficiency, while levels >18 mcg/dL generally exclude adrenal insufficiency. If the morning cortisol is 3-15 mcg/dL, confirmation is performed with a rapid ACTH (cosyntropin/Synacthen) stimulation test using 250 mcg ACTH IV, measuring cortisol at baseline, 30 minutes, and 60 minutes. A peak cortisol response >18 mcg/dL (≈500 nmol/L) suggests normal adrenal reserve, whereas failure to reach this threshold supports adrenal insufficiency. After confirming inadequate cortisol response, measuring plasma ACTH helps distinguish primary from secondary disease: ACTH >200 pg/mL supports primary adrenal insufficiency, while normal or low ACTH suggests secondary adrenal insufficiency. In critical illness–related corticosteroid insufficiency, a low-dose 1 mcg ACTH stimulation approach may be used, and an inadequate response may be defined by a cortisol level <25 mcg />L or an increment <9 mcg />L above baseline, depending on the clinical context.
Further evaluation aims to identify the cause. 21-hydroxylase antibodies are present in approximately 90% of autoimmune adrenalitis; if negative, adrenal imaging (typically CT) is recommended to assess for infection, hemorrhage, malignancy, or infiltrative disease. Tuberculosis evaluation may include PPD or interferon-gamma release testing. Imaging is not required to establish the diagnosis but can support etiology: small adrenal glands may indicate long-standing autoimmune atrophy or chronic tuberculosis, whereas enlarged glands can suggest early TB or other potentially treatable infiltrative processes. Chest radiography may show a small cardiac silhouette, and abdominal radiography can occasionally reveal adrenal calcifications in TB or fungal disease.
Management includes both chronic hormone replacement and urgent treatment of adrenal crisis. Patients should be educated on long-term monitoring of electrolytes, blood pressure, and weight, and generally advised to maintain a liberal sodium intake, especially in primary disease. They should carry a MedicAlert bracelet and an emergency kit containing injectable hydrocortisone, and both patients and partners should be trained to administer intramuscular steroids if vomiting or impaired consciousness prevents oral intake. Bone density monitoring may be considered because long-term glucocorticoid exposure increases osteoporosis risk.
Adrenal crisis is a life-threatening emergency characterized by circulatory collapse, dehydration, nausea/vomiting, hypoglycemia, hyperkalemia, and often severe hypotension. Treatment must begin immediately and should not be delayed for confirmatory testing. Initial steps include establishing large-bore IV access, drawing blood for electrolytes, glucose, cortisol, and ACTH, and rapidly infusing 2–3 liters of isotonic saline (0.9% NaCl) or dextrose-containing saline if hypoglycemia is present, with careful monitoring for fluid overload. Hydrocortisone 100 mg IV should be administered immediately and continued 100 mg every 6 hours, alongside supportive care and aggressive identification and treatment of precipitating causes such as infection, hemorrhage, or trauma. After stabilization, IV fluids are continued more slowly over 24–48 hours, the diagnosis is confirmed if previously unknown, glucocorticoids are tapered to maintenance dosing over 1–3 days as clinically appropriate, and mineralocorticoid replacement with fludrocortisone is started when stress-dose hydrocortisone is reduced and saline infusion is stopped.
Chronic treatment of primary adrenal insufficiency requires both glucocorticoid and mineralocorticoid replacement. A common regimen is hydrocortisone 15–20 mg on awakening with 5–10 mg in the early afternoon, or an alternative prednisone schedule such as 5 mg in the morning and 2.5 mg at bedtime, tailored to symptoms and avoidance of overtreatment. Fludrocortisone is generally required in primary disease, often starting around 0.1 mg daily (adjusted within a wider range based on orthostatic symptoms, blood pressure, edema, serum potassium, and plasma renin activity). Patients must be taught “sick day rules,” typically increasing glucocorticoid dosing two- to threefold for minor febrile illnesses for a few days without changing fludrocortisone dose, and using parenteral steroids if vomiting, diarrhea, severe illness, trauma, or surgery occurs. Stress-dose steroid coverage varies by severity: moderate illness may require hydrocortisone 50 mg twice daily orally or IV, while severe illness or shock can require hydrocortisone 100 mg IV every 8 hours with rapid tapering as recovery occurs. Minor procedures under local anesthesia often need no additional supplementation, whereas more stressful procedures may require a single 100 mg IV hydrocortisone dose just before the procedure, and major surgery typically requires 100 mg IV before induction followed by continued dosing for at least 24 hours with tapering.
In secondary adrenal insufficiency, mineralocorticoid replacement is usually unnecessary, and clinical clues include absence of hyperpigmentation and evidence of other pituitary hormone deficiencies such as hypothyroidism or hypogonadism. A critical safety point is that patients with both hypothyroidism and adrenal insufficiency should receive glucocorticoid replacement before thyroid hormone replacement, because thyroid hormone can increase cortisol clearance and precipitate adrenal crisis. Withdrawal from chronic exogenous steroid therapy should be gradual in patients treated for more than several weeks, with taper schedules individualized to dose and duration, and confirmation of hypothalamic–pituitary–adrenal axis recovery using appropriate stimulation testing when clinically indicated.
- Published on
KembaraXtra- Medicine – Adult-Onset Still Disease
Adult-onset Still disease (AOSD) is a rare systemic inflammatory disorder characterized by episodes of high-spiking fever, an evanescent rash, and arthralgias/arthritis, often accompanied by lymphadenopathy, hepatosplenomegaly, and markedly elevated serum ferritin. Many patients report a prodromal sore throat, sometimes preceding systemic symptoms. The daily (quotidian) fever pattern is a striking feature, and inflammatory arthritis can become progressive and destructive over time, leading to joint damage and disability in a subset of patients.
AOSD has several synonyms, including Still disease, systemic juvenile idiopathic arthritis (systemic JIA), and Wissler (Wissler-Fanconi) syndrome. The ICD-10-CM code is M06.1. Because it is uncommon, definitive epidemiologic data are limited, but prevalence has been reported between 1 and 34 per 1,000,000, with incidence around 0.1 to 0.4 per 100,000. A bimodal age distribution is described, with peaks around 15–25 and 36–46 years, and there is no consistent gender predisposition.
Infectious triggers are suspected in genetically susceptible individuals, as onset or relapse may follow a viral-like prodrome with pharyngitis, malaise, fever, and rash, although no single organism has been consistently implicated. Studies suggest a genetic component, with some associations reported between AOSD and certain HLA types (including class II DRB115 and DRB112 for susceptibility, and class I B35 with self-limited disease, DR2/DR5 with more chronic disease), though findings have not been consistently verified across populations.
Clinically, the “cardinal” triad of AOSD is fever, arthralgias/arthritis, and rash, and it occurs in most patients. Fever typically follows a quotidian pattern with spikes often occurring in the late afternoon or evening, frequently exceeding 102°F (38.9°C) and lasting a few hours before returning to normal. A “double quotidian” pattern with a second early-morning spike occurs in some cases. The classic rash is a salmon-pink, nonpruritic, maculopapular eruption most often involving the trunk and proximal extremities. The rash may appear with fever and fade when afebrile, which can make it easy to miss; Koebner phenomenon can occur. Arthralgias and myalgias are very common, and inflammatory arthritis often presents as symmetric polyarthritis affecting larger joints, with up to half of patients developing progressive destructive arthritis. Other manifestations may include sore throat, lymphadenopathy, hepatosplenomegaly, and serositis. Cardiac involvement such as pericarditis can occur and, in severe cases, can progress to tamponade, warranting prompt recognition and treatment.
The pathogenesis is not fully defined, but the disease appears driven by innate immune dysregulation and abnormal macrophage activation. Elevated proinflammatory cytokines are commonly described, including IL-1, IL-6, IL-18, TNF-α, interferon-γ, and others. More recently, increased circulating markers related to neutrophil extracellular traps (NETs) have been observed in active disease, with reductions after treatment, though the clinical implications continue to be studied.
There is no single diagnostic test that is pathognomonic for AOSD. Diagnosis is clinical and laboratory-based and is fundamentally a diagnosis of exclusion, requiring evaluation for infectious, neoplastic, and other inflammatory causes of fever and systemic illness. Laboratory abnormalities often include neutrophilic leukocytosis (commonly WBC >12 with >80% PMNs), very elevated inflammatory markers (often ESR >50 and CRP markedly elevated), normocytic anemia, thrombocytosis, hypoalbuminemia, and mild transaminitis. Creatine kinase (CPK) is typically normal even when myalgias are prominent. Hyperferritinemia is a particularly suggestive feature, and ferritin levels can exceed five times the upper limit of normal. Autoantibodies typical of other rheumatologic diseases are usually absent, with negative rheumatoid factor and negative ANA supporting (but not confirming) the diagnosis.
Imaging can support assessment of systemic involvement and complications. Plain radiographs may show early nonspecific changes such as soft-tissue swelling, effusions, or periarticular osteopenia, while later disease can demonstrate destructive arthropathy—classically in the wrists with joint-space narrowing and eventual ankylosis, and in hips with progressive joint destruction. CT or MRI may demonstrate lymphadenopathy, hepatosplenomegaly, and early bony or soft-tissue findings. FDG PET/CT may show increased uptake in spleen, bone marrow, and reactive lymph nodes, though these findings are not specific and must be interpreted in context.
Multiple classification/diagnostic criteria sets exist. The Yamaguchi criteria are widely used because they are sensitive and practical. The Fautrel criteria are more specific but require measurement of glycosylated ferritin, which is not routinely available in many settings. Regardless of criteria, careful exclusion of mimics is essential.
Prognosis is often favorable overall, with reported 5-year survival around 90%–95%, but many patients require long-term treatment to control inflammation and prevent relapse or progressive joint damage. Clinical course typically falls into one of three patterns: a self-limited/monophasic course with remission within a year, an intermittent/relapsing course with recurrent flares separated by remission, or a chronic/progressive course dominated by persistent arthritis and erosive destruction. Features associated with progression to chronic articular disease include polyarthritis, large-joint involvement, and very high ferritin levels at presentation.
Treatment depends on severity and organ involvement. Mild disease may respond to full-dose NSAIDs alone, though sustained control occurs in a minority. Most patients require systemic glucocorticoids, particularly when systemic symptoms are prominent or there is significant organ involvement. For steroid-sparing and control of arthritis, methotrexate is commonly used. Biologic therapy is frequently effective, especially for refractory disease or patients who cannot taper steroids. IL-1 blockade (such as anakinra or canakinumab) is often highly effective for systemic symptoms and inflammation. IL-6 inhibitors (such as tocilizumab or sarilumab) and TNF inhibitors (such as etanercept or infliximab) are also used, sometimes in combination with methotrexate. Response is typically reassessed after 2–3 months, and nonresponders are often switched to a biologic with a different mechanism. After prolonged remission, cautious tapering may be attempted. In severe or refractory cases, other therapies (including IVIG, and less commonly agents like rituximab or abatacept) have been reported with limited evidence.
A critical complication to recognize is macrophage activation syndrome (MAS), also referred to as reactive hemophagocytic lymphohistiocytosis. It occurs in a notable minority of AOSD patients and can be life-threatening, with substantial mortality. MAS can resemble a severe AOSD flare, but clues that raise suspicion include cytopenias (leukopenia and thrombocytopenia), hypofibrinogenemia, hypertriglyceridemia, and sometimes a paradoxical normalization of ESR despite clinical worsening. Bone marrow aspiration demonstrating hemophagocytosis is considered the diagnostic gold standard. Initial management commonly includes pulse-dose corticosteroids, IVIG, and cytokine-directed biologic therapy (often IL-1 or IL-6 blockade), alongside intensive supportive care.
- Published on
KembaraXtra- Medicine – Alcohol Use Disorder
Alcohol use disorder (AUD) describes problematic patterns of alcohol use that lead to clinically significant impairment or distress, and it includes a spectrum from hazardous use to dependence and withdrawal syndromes. “Moderate drinking” is commonly defined as up to two standard drinks per day for men and one standard drink per day for women and adults older than 65 years. “Hazardous” or “at-risk” drinking is defined as more than 14 drinks per week or more than 4 drinks per occasion for men, and 4 or more drinks on one occasion or 8 or more drinks per week for women. Alcohol withdrawal is defined by the development of characteristic symptoms after cessation or reduction of heavy and prolonged alcohol use, including autonomic hyperactivity, tremor, insomnia, nausea/vomiting, transient hallucinations or illusions, psychomotor agitation, anxiety, and grand mal seizures; symptoms must cause clinically significant distress or impairment and not be better explained by another condition.
AUD is also referred to as alcohol dependence syndrome, alcoholism, substance abuse, and alcohol withdrawal syndrome. ICD-10-CM codes fall under F10 (mental and behavioral disorders due to alcohol use), including F10.1 (harmful use), F10.2 (dependence syndrome), F10.3 (withdrawal state), F10.4 (withdrawal state with delirium), F10.5 (psychotic disorder), and F10.6 (amnesic syndrome). In U.S. clinical settings, alcohol-related problems are suggested by the clinical history in roughly 15% to 20% of primary care and hospitalized patients, with substantial economic and health impacts. AUD prevalence in adults (≥18 years) is commonly cited around 7%, with peak incidence in early adulthood and a common initial treatment age range in the mid-30s to mid-40s. Lifetime risk is higher in men than women. Risk is increased by family history, and AUD is more common in certain ancestry groups as described in clinical epidemiology summaries.
Patients may present with a wide range of physical and clinical findings related to intoxication, chronic use, or complications. Common clinical clues include recurring minor trauma, gastrointestinal bleeding from gastritis or varices, pancreatitis (acute or chronic), liver disease, alcohol odor on breath, tremulousness, tachycardia, peripheral neuropathy, and recent memory loss. Etiology is multifactorial, with both genetic and social determinants contributing. Commonly described risk factors include unstable social environments, unemployment, divorce, recurrent depression, addiction to other substances (including tobacco), and occupational patterns such as working very long hours.
Diagnosis and initial evaluation rely heavily on screening and history. Screening tools commonly used include CAGE, AUDIT-C, TWEAK/TACE (especially in pregnancy), and CRAFFT (adolescents). CAGE asks about the need to cut down, annoyance by criticism, guilt, and eye-openers; a positive screen should prompt further assessment. AUDIT-C focuses on alcohol frequency and quantity and provides a structured score (0–12), with ≥4 in men and ≥3 in women suggesting problematic drinking requiring more evaluation. A single-question screen (“When was the last time you had more than X drinks in a day?” where X is 5 for men and 4 for women) can also identify unhealthy use when anchored to a recent timeframe. Laboratory tests alone do not diagnose AUD but are useful for identifying complications and nutritional deficiencies. Common findings include elevated gamma-glutamyltransferase (GGT), abnormal AST/ALT (which may be normal or low in advanced liver disease), low albumin, electrolyte abnormalities (hypophosphatemia, hypomagnesemia), macrocytosis with elevated MCV on CBC, positive stool occult blood when gastritis/varices are present, and low vitamin levels including folate, B12, B6, and especially thiamine (B1). Imaging is not routinely required unless trauma is suspected; abdominal ultrasound or CT may show fatty liver or cirrhosis in advanced disease.
Nonpharmacologic treatment is a foundation of care and includes structured psychosocial therapies such as twelve-step facilitation, cognitive behavioral therapy, and motivational enhancement therapy. Coexisting depression should be treated alongside alcohol cessation rather than delayed, because mood disorders commonly coexist and influence relapse risk. Detoxification is not sufficient as stand-alone care and should function as a bridge into a longer-term treatment plan.
Alcohol withdrawal syndrome is managed based on severity and timing from the last drink. Blood ethanol typically declines at about 20 mg/dL per hour. Early withdrawal (“tremulous state”) often begins within 6 to 8 hours after the last drink (or 12 to 48 hours after reduction), peaking around 24 to 36 hours, with tremor, insomnia, mild agitation, and tachycardia. Depending on support system, comorbidities, and risk factors for severe withdrawal, detoxification may occur in outpatient or inpatient settings. Inpatient care includes monitoring (often with standardized withdrawal charts), seizure precautions, and symptom-titrated sedation. Benzodiazepines are the cornerstone of withdrawal management and are used either as fixed-dose tapers or symptom-triggered regimens. Symptom-triggered protocols often use the CIWA-Ar scale to guide dosing; patients with mild symptoms can sometimes be monitored outpatient, while higher CIWA-Ar scores and high-risk histories warrant inpatient detoxification. Beta-blockers can help control tachycardia and hypertension but should not be used alone because they do not prevent seizures or delirium; clonidine can reduce autonomic symptoms in mild to moderate cases but similarly does not prevent seizures or delirium. Vitamin replacement is essential, especially thiamine, and thiamine should be administered before IV dextrose to reduce the risk of precipitating Wernicke encephalopathy. Hydration and correction of electrolytes (including magnesium and phosphate) are often required.
Alcoholic hallucinosis consists of predominantly auditory hallucinations (sometimes visual/tactile/olfactory) that often peak 24 to 36 hours after abstinence and can resemble a primary psychotic disorder, but typically occurs without the marked clouding of sensorium seen in delirium tremens. Withdrawal seizures usually occur within 7 to 30 hours after cessation (often peaking around 13 to 24 hours) and are typically generalized; focal deficits, prolonged confusion, or fever should prompt evaluation for alternative causes (including imaging and lumbar puncture when indicated). Delirium tremens (DTs) is the most severe withdrawal state, usually occurring within the first week after reduction or cessation of heavy intake, commonly peaking around 72 to 96 hours, and characterized by profound confusion, tremor, vivid hallucinations, and marked autonomic hyperactivity; untreated mortality is significant. DTs require close monitoring, aggressive supportive care, and adequate benzodiazepine sedation (sometimes with agents such as lorazepam, chlordiazepoxide, diazepam, or midazolam in titratable settings), along with correction of fluids, electrolytes, and coexisting medical problems.
Long-term (chronic) treatment focuses on relapse prevention and sustained recovery using both psychosocial support and, when appropriate, pharmacotherapy. Acamprosate supports maintenance of abstinence after detoxification and is typically dosed as 666 mg three times daily; it should be avoided in severe renal impairment. Naltrexone (oral or extended-release monthly injection) reduces the rewarding effects of alcohol and can reduce heavy drinking; it must be avoided in acute hepatitis/hepatic failure and in people using opioids, as it can precipitate opioid withdrawal. Disulfiram causes an aversive reaction to alcohol ingestion by blocking aldehyde dehydrogenase, but is now used less often. Agents such as topiramate, baclofen, or gabapentin may be considered second line in moderate to severe AUD, with some guidance suggesting topiramate may be preferable in certain cases. Pharmacologic therapy is generally avoided in pregnant or breastfeeding individuals.
Disposition and referral are key components of management. Community supports such as Alcoholics Anonymous, Adult Children of Alcoholics, and family supports like Al-Anon or Al-A-Teen can be helpful. Inpatient detoxification is relatively indicated for patients with a history of DTs or withdrawal seizures, severe withdrawal symptoms, significant psychiatric or medical comorbidities, pregnancy, multiple prior detoxifications, recent high levels of alcohol intake, or lack of a reliable support network. Even when detoxification is successful, long-term outcomes depend heavily on engagement in ongoing treatment and social support, because relapse is common without sustained intervention.
- Published on
KembaraXtra- Medicine – Alcoholic Hepatitis
Alcoholic hepatitis (AH) is a severe, progressive inflammatory and cholestatic liver disease that occurs in the setting of long-term heavy alcohol use—commonly described as roughly 60–80 g/day in men and 20–40 g/day in women. It is characterized by a rapid onset of jaundice, hepatomegaly, generalized malaise, and features of a systemic inflammatory response. Patients often have a long history of heavy intake, frequently exceeding 100 g of alcohol daily for two or more decades, with a typical presentation age in the 40s to 50s, usually before age 60. While AH is more common in men overall, women may develop AH after a shorter duration and lower cumulative exposure. Risk factors described include poor nutrition, obesity, female sex, Hispanic ethnicity, drinking multiple alcohol types, and drinking between meals.
Clinically, AH often presents with jaundice developing within about 60 days of heavy alcohol consumption (often >50 g/day for at least 6 months), with jaundice duration typically less than 3 months. Patients may report right upper quadrant or epigastric pain, nausea or vomiting, malaise, anorexia, low-grade fever, abdominal distention (often from ascites), weight loss or malnourishment, and proximal muscle wasting or weakness. With worsening hepatic dysfunction, complications can include gastrointestinal bleeding and encephalopathy (confusion, lethargy). On examination, common findings include jaundice, ascites, a tender enlarged liver, tachycardia or tachypnea, hypotension, peripheral edema, shifting dullness from ascites, splenomegaly, and sometimes a hepatic bruit. If cirrhosis coexists, stigmata such as gynecomastia, spider angiomata, altered hair distribution, and muscle wasting may be present. Fever should prompt evaluation for infection, including spontaneous bacterial peritonitis, urinary tract infection, and pneumonia.
Diagnosis is primarily clinical and supported by characteristic laboratory patterns, while excluding competing causes of acute hepatitis and cholestasis such as hepatitis B or C, nonalcoholic steatohepatitis, drug-induced liver injury, hemochromatosis, and cholangitis. A detailed alcohol history is essential, and screening for alcohol misuse can be supported with tools such as the AUDIT questionnaire. Laboratory findings commonly include AST elevation (>45 U/L but typically <500 u />) with an AST:ALT ratio ≥2:1, total bilirubin often >5 mg/dL, and prolonged PT/INR. Additional supportive findings may include elevated GGT, elevated CRP, electrolyte and micronutrient abnormalities (such as hypokalemia, hypomagnesemia, low zinc, hypophosphatemia), hypoalbuminemia, hyperferritinemia, and CBC abnormalities (leukocytosis with bandemia, anemia, thrombocytopenia, and an elevated MCV). Testing is also used to rule out alternative diagnoses, including viral hepatitis serologies and other targeted labs (e.g., ferritin/transferrin saturation, alkaline phosphatase, alpha-fetoprotein when appropriate). Imaging is used both to evaluate liver morphology and to exclude other causes; abdominal ultrasound is typically the imaging study of choice to assess for gallstones, biliary obstruction, liver abscess, or hepatocellular carcinoma. Liver biopsy is rarely required, but may be helpful when the diagnosis is uncertain, to assess coexisting disease, or to exclude alternative pathology; typical histology can include steatosis, hepatocyte ballooning and necrosis, Mallory–Denk bodies, perivenular fibrosis, and lobular/portal inflammation.
Management is commonly framed around three pillars: (1) severity assessment, (2) supportive care with abstinence and nutrition, and (3) pharmacologic therapy for severe disease when indicated. Severity is often assessed with scoring systems such as Maddrey Discriminant Function (MDF) and MELD, and sometimes the Glasgow alcoholic hepatitis score. Severe AH is often defined by MDF ≥32, MELD >20–21, and/or presence of hepatic encephalopathy; these thresholds are associated with high short-term mortality and generally warrant hospitalization. Abstinence from alcohol, together with nutritional support, is the cornerstone of treatment and improves both short- and long-term survival. Nonpharmacologic supports for abstinence include cognitive behavioral therapy, motivational interviewing, and Alcoholics Anonymous attendance, while pharmacologic relapse-prevention aids may include agents such as naltrexone, acamprosate, or baclofen when appropriate. Monitoring abstinence can include breath testing, urine drug screening for recent use, or hair testing for ethyl glucuronide for longer windows, depending on clinical context. Smoking cessation and treatment of other substance use are also recommended to reduce oxidative stress and improve outcomes.
Nutrition is emphasized because many patients have protein-calorie malnutrition and vitamin/mineral deficiencies. Support commonly includes liberal vitamin supplementation (notably thiamine, folate, and vitamin K), mineral supplementation (generally avoiding iron unless specifically indicated), careful calorie counting with increased caloric targets, and protein intake around 1.2–1.5 g/kg/day of ideal body weight, with possible temporary restriction only in severe encephalopathy. Fluid management is individualized, especially in patients with ascites or renal dysfunction.
For severe alcoholic hepatitis, glucocorticoids may be used in selected patients—commonly prednisolone 40 mg/day for 28 days followed by a taper—aiming to reduce hepatic inflammation and injury. Steroid therapy is not universally beneficial in all studies and must be weighed against contraindications such as active infection or gastrointestinal bleeding. Clinical response should be reassessed during treatment, and therapy is typically discontinued in nonresponders based on bilirubin trends and prognostic models. For patients who cannot receive corticosteroids, pentoxifylline has been used historically, although evidence is limited and it is not effective as rescue therapy for steroid nonresponders.
Liver transplantation can be considered in carefully selected patients with severe disease (e.g., very high MELD and poor response to medical therapy). Early liver transplantation has been associated with favorable survival in selected candidates, though programs apply strict psychosocial evaluation and relapse-risk assessment. Historically, many centers required 6 months of sobriety, but selection is increasingly individualized and not based solely on time abstinent. Severe AH may require ICU-level care and multidisciplinary referral, including gastroenterology/hepatology, nutrition services, nephrology for hepatorenal syndrome or renal failure, infectious disease for fever/leukocytosis, and neurology for altered mental status or seizures. Ongoing follow-up includes monitoring metabolic panels and liver tests, reinforcing abstinence, and—if cirrhosis is present—surveillance strategies such as periodic alpha-fetoprotein testing and liver ultrasound for hepatocellular carcinoma, along with vaccination against hepatitis A and B and routine adult immunizations when appropriate.
- Published on
KembaraXtra- Medicine – Alopecia
Alopecia refers to involuntary hair loss, most commonly affecting the scalp but potentially involving any hair-bearing area of the body. Alopecia is broadly classified into nonscarring (noncicatricial) and scarring (cicatricial) forms. Nonscarring alopecia is characterized by hair loss without permanent follicular destruction, scarring, or skin atrophy, whereas scarring alopecia results in irreversible hair loss due to follicular damage accompanied by inflammation, fibrosis, and loss of follicular openings.
Among nonscarring alopecias, alopecia areata is an autoimmune condition causing patchy hair loss on the scalp, eyebrows, eyelashes, or beard area, and may progress to alopecia totalis (complete scalp hair loss) or alopecia universalis (complete loss of body hair). Androgenetic alopecia (AGA) is the most common form of hair loss and results from genetically determined follicular sensitivity to androgens. In men, it presents as bitemporal recession, frontal thinning, and vertex balding (male pattern hair loss), while in women it manifests as diffuse central scalp thinning with preservation of the frontal hairline (female pattern hair loss). Women may initially notice increased shedding and reduced ponytail volume years before visible thinning develops.
The epidemiology of alopecia varies by etiology. Alopecia areata affects approximately 1% of the U.S. population by age 50 and occurs equally in both sexes. Androgenetic alopecia affects up to 50% of Caucasian men by age 50, with lower prevalence and later onset in Asian and African-American men. By age 70, approximately 40% of women are affected, particularly after menopause. Genetic factors play a significant role, especially in androgenetic alopecia, which is polygenic with variable penetrance, while certain scarring alopecias are more common in individuals with coarse or tightly curled hair.
The causes of alopecia are diverse and include autoimmune disorders, hormonal changes, infections, medications, nutritional deficiencies, physical or psychological stress, and trauma. Nonscarring alopecia may result from altered hair cycling (as in telogen effluvium or anagen effluvium), follicular miniaturization (as in androgenetic alopecia), hair shaft damage (from traction, trichotillomania, or cosmetic overprocessing), or immune-mediated follicular attack (as in alopecia areata). Scarring alopecia may be caused by inflammatory or autoimmune diseases such as lichen planopilaris or discoid lupus erythematosus, infections like severe tinea capitis with kerion formation, neoplasms, or congenital conditions.
Clinical evaluation begins with a thorough history, focusing on the onset, duration, and pattern of hair loss; recent stressors or illnesses; medication use; nutritional status; hair care practices; family history; and associated systemic or dermatologic symptoms. Physical examination assesses the distribution and extent of hair loss, presence of inflammation or scarring, hair shaft abnormalities, and associated findings such as virilization in women or nail changes in alopecia areata. Characteristic findings include exclamation-point hairs in alopecia areata, broken hairs of varying lengths in traumatic alopecia, and shiny atrophic skin with loss of follicular openings in scarring alopecia.
Diagnostic evaluation may include a hair pull test, where removal of six or more hairs from a gentle pull suggests active shedding, most commonly seen in telogen effluvium. Scalp biopsy is essential when scarring alopecia is suspected and should be performed with both vertical and horizontal sections for optimal histopathologic assessment. A trichogram may help quantify the proportion of anagen versus telogen hairs. Laboratory testing is guided by clinical suspicion and may include complete blood count, iron studies, thyroid function tests, autoimmune markers, and hormonal evaluation in women with signs of hyperandrogenism.
The differential diagnosis of nonscarring alopecia includes telogen effluvium, characterized by diffuse shedding following physiologic or psychological stress; androgenetic alopecia, with its characteristic patterned thinning; alopecia areata, presenting with well-demarcated patches of hair loss and autoimmune features; tinea capitis, especially in children; and traumatic alopecia, including traction alopecia and trichotillomania. Scarring alopecias include conditions such as lichen planopilaris, discoid lupus erythematosus, and inflammatory tinea capitis with kerion formation, all of which may lead to permanent hair loss if untreated.
Treatment depends on the underlying cause. Telogen effluvium is typically self-limited, with hair regrowth occurring within months once the inciting factor is removed. Androgenetic alopecia is managed with topical minoxidil in both sexes and oral finasteride in men; discontinuation of therapy results in recurrence of hair loss. Additional options include antiandrogens in selected women, hair transplantation, cosmetic camouflage, and low-level light therapy. Alopecia areata may resolve spontaneously, but treatments include topical, intralesional, or systemic corticosteroids, topical immunotherapy, and newer agents such as oral JAK inhibitors, which are now approved for severe disease in adults. Tinea capitis requires systemic antifungal therapy, and inflammatory kerion may necessitate adjunctive corticosteroids. Traction alopecia improves with elimination of the offending hairstyle or practice, while scarring alopecias focus on early inflammation control to prevent further permanent loss.
Patients with suspected scarring alopecia, treatment-resistant disease, or diagnostic uncertainty should be referred to dermatology. Education and counseling are essential, as hair loss can have a profound psychological impact. For patients with alopecia areata, support organizations and patient education resources can provide valuable guidance and reassurance.
- Published on
KembaraXtra- Medicine – Primary Aldosteronism (Hyperaldosteronism)
Primary aldosteronism is a group of disorders characterized by autonomous and excessive secretion of aldosterone, leading to renal sodium retention, suppression of plasma renin, and secondary hypertension. The condition classically presents with hypertension, hypokalemia, and metabolic alkalosis, although many patients may be normokalemic. Because aldosterone excess directly affects cardiovascular and renal systems, primary aldosteronism is now recognized as a common and clinically important cause of secondary hypertension.
Epidemiologic studies show that primary aldosteronism is far more prevalent than previously believed, particularly among patients with resistant hypertension. Current estimates suggest it may be present in 17% to nearly 27% of patients with resistant hypertension, with prevalence increasing as the severity of hypertension worsens. Familial forms of hyperaldosteronism are uncommon but should be suspected in patients with early-onset hypertension (before age 21), a family history of primary aldosteronism, or a family history of stroke before age 40.
The most common causes of primary aldosteronism include bilateral idiopathic adrenal hyperplasia, which accounts for approximately 60% to 70% of cases, and unilateral aldosterone-producing adenomas (Conn syndrome), which account for about 30% to 40%. Less common causes include unilateral adrenal hyperplasia, familial hyperaldosteronism, adrenal carcinoma, and ectopic aldosterone production. The underlying cause is important because it directly determines treatment strategy.
Clinically, many patients are asymptomatic aside from hypertension. When present, manifestations may include resistant hypertension, spontaneous or diuretic-induced hypokalemia, muscle weakness, fatigue, or a history of early cardiovascular events. A family history of early hypertension or stroke should heighten suspicion. Because symptoms may be subtle or absent, a high index of suspicion is required, particularly in patients whose blood pressure remains uncontrolled despite multiple antihypertensive agents.
Diagnosis begins with recognition of the biochemical pattern of suppressed plasma renin activity and elevated serum aldosterone levels, typically with aldosterone concentrations exceeding 15 ng/dL. Screening is recommended in patients with resistant hypertension, early-onset hypertension, hypokalemia, adrenal incidentalomas, sleep apnea, or a strong family history of hypertension or stroke. The aldosterone-to-renin ratio (ARR) is commonly used as an initial screening test, although its sensitivity is limited. When results are inconclusive, 24-hour urinary aldosterone excretion under aldosterone-suppressing conditions may be required for confirmation.
Routine laboratory findings are not diagnostic but may support the diagnosis, including hypokalemia, metabolic alkalosis, and occasionally mild hypernatremia. Once biochemical confirmation is obtained, imaging is performed to determine whether aldosterone excess is unilateral or bilateral. Adrenal CT scanning is the preferred imaging modality, as adrenal adenomas are typically lipid-rich and well visualized on CT. MRI may be used as an alternative. However, imaging alone cannot reliably distinguish unilateral from bilateral disease.
To definitively differentiate unilateral from bilateral aldosterone secretion, adrenal vein sampling (AVS) is recommended in most patients who are surgical candidates. This distinction is critical, as unilateral disease is best treated surgically, whereas bilateral disease requires medical therapy. AVS should be performed by experienced interventional radiologists to ensure accurate results.
Management includes both nonpharmacologic and pharmacologic strategies. Lifestyle measures such as regular blood pressure monitoring, a low-sodium diet, tobacco avoidance, weight management, and regular exercise are recommended for all patients. Acute management focuses on controlling hypertension and correcting hypokalemia, typically using mineralocorticoid receptor antagonists such as spironolactone or eplerenone, or potassium-sparing agents like amiloride.
Long-term medical therapy is the mainstay for patients with bilateral adrenal hyperplasia. Spironolactone is usually initiated at a low dose and titrated upward every two weeks to achieve a normal serum potassium level without supplementation. Eplerenone is an effective alternative with fewer antiandrogenic side effects, such as gynecomastia or menstrual irregularities. Amiloride may be used in patients who cannot tolerate mineralocorticoid receptor antagonists.
For patients with unilateral aldosterone-producing adenomas or unilateral adrenal hyperplasia, laparoscopic adrenalectomy is the treatment of choice. Surgical treatment typically resolves hypokalemia and improves blood pressure control, although hypertension persists in 40% to 65% of patients postoperatively. Complete resolution of hypertension is more likely in younger patients, those with a shorter duration of hypertension, fewer preoperative antihypertensive medications, no family history of hypertension, and higher aldosterone-to-renin ratios.
Overall, treatment of primary aldosteronism—whether surgical or medical—results in meaningful improvements in blood pressure control, potassium balance, and cardiovascular and renal outcomes. Untreated disease is associated with higher risks of stroke, myocardial infarction, atrial fibrillation, left ventricular hypertrophy, and decline in kidney function compared with essential hypertension. These risks are significantly reduced with appropriate therapy, and in many cases, surgical treatment lowers cardiovascular risk to below that of matched patients with essential hypertension.
- Published on
KembaraXtra- Medicine – Allergic Rhinitis
Allergic rhinitis (AR) is an immunoglobulin E (IgE)–mediated hypersensitivity reaction to inhaled environmental allergens that leads to inflammation of the nasal mucosa. This inflammatory process is driven primarily by type 2 helper T (Th2) cells and results in the characteristic symptoms of sneezing, rhinorrhea, nasal pruritus, and nasal congestion. Allergic rhinitis may be seasonal, triggered by pollens, or perennial, caused by year-round allergens such as dust mites, molds, and animal dander.
Allergic rhinitis is highly prevalent, affecting 10% to 30% of the U.S. population and up to 40% of children, with substantial impact on quality of life, school performance, and workplace productivity. The mean age of onset is between 8 and 12 years, and approximately 80% of cases develop before age 20. Sensitization to aeroallergens is uncommon before the age of one year. Among patients presenting to primary care with nasal complaints, allergic rhinitis accounts for 30% to 60% of cases.
Clinically, allergic rhinitis is distinguished from nonallergic rhinitis by the presence of sneezing, nasal itching, and ocular pruritus. Both allergic and nonallergic rhinitis may cause nasal congestion, postnasal drip, and cough. Additional symptoms include fatigue, irritability, reduced sense of smell, and a sensation of ear fullness. Physical examination often reveals pale or violaceous, edematous nasal turbinates caused by venous engorgement, a feature that helps distinguish allergic rhinitis from viral rhinitis, which typically presents with erythematous mucosa. Other findings may include clear nasal discharge, posterior pharyngeal drainage, conjunctival injection, throat erythema, and occasionally nasal polyps.
The most common triggers of allergic rhinitis include pollens (trees in spring, grasses in summer, and weeds in fall), as well as dust mites, mold spores, and animal allergens. Nonallergic irritants such as smoke, strong odors, and pollution may exacerbate symptoms in both allergic and nonallergic rhinitis but do not represent the primary mechanism of disease.
Diagnosis is largely clinical, based on history and physical examination. Many patients do not require formal diagnostic testing if symptoms and triggers are typical. A seasonal pattern of symptoms can help identify the likely allergen source, whereas year-round symptoms suggest perennial allergens. Allergy testing, either by skin testing or serum-specific IgE testing, may be useful in patients with persistent symptoms despite standard therapy, those considering allergen immunotherapy, or when precise identification of allergens is necessary for avoidance strategies.
Management begins with nonpharmacologic measures, including allergen avoidance when feasible. Strategies include dust mite control with mattress and pillow encasements, removal of carpeting and allergen-collecting items from the bedroom, use of HEPA air filtration, and limiting exposure to pets in sensitized individuals. Nasal saline sprays or irrigations are effective adjunctive therapies that reduce nasal dryness, congestion, and allergen load.
For pharmacologic treatment, intranasal corticosteroids are the preferred first-line therapy for most patients with allergic rhinitis. These agents effectively reduce nasal inflammation and improve all major symptoms, although maximal benefit may take at least one week of regular use. In patients with moderate to severe disease, combination therapy with an intranasal corticosteroid and an intranasal antihistamine provides greater symptom control than either agent alone. Oral second-generation antihistamines may be helpful for persistent ocular symptoms but offer little additional benefit when combined with intranasal corticosteroids for nasal symptoms. Montelukast should be reserved for patients who cannot tolerate or do not respond to first-line therapies, and intranasal ipratropium may be considered when rhinorrhea is the predominant complaint.
For patients with persistent or severe symptoms despite optimal medical therapy, allergen immunotherapy may be considered. Both subcutaneous and sublingual immunotherapy can significantly reduce symptoms and medication use, with approximately 80% of patients reporting improvement. Immunotherapy is contraindicated in patients with uncontrolled asthma, a history of severe reactions to immunotherapy, and—specifically for sublingual therapy—those with eosinophilic esophagitis.
Overall, the prognosis of allergic rhinitis is excellent. Most patients achieve good symptom control with appropriate avoidance strategies and medical therapy. Referral to an allergist or otolaryngologist is appropriate for patients with moderate to severe disease, those unresponsive to treatment, or individuals interested in immunotherapy.
- Published on
KembaraXtra- Medicine – Alpha-1-Antitrypsin Deficiency
Alpha-1-antitrypsin deficiency (AATD) is an inherited genetic disorder caused by deficiency or dysfunction of the protease inhibitor alpha-1-antitrypsin (AAT). The condition most commonly results from homozygous carriage of the SERPINA1 Z allele (PI*ZZ genotype). This mutation leads to production of an abnormal AAT protein (Z-AAT) that accumulates within hepatocytes while circulating levels of functional AAT are markedly reduced. The resulting imbalance predisposes affected individuals to early-onset pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and progressive liver disease, including cirrhosis and hepatocellular carcinoma.
Alpha-1-antitrypsin deficiency is underrecognized but accounts for approximately 1% to 5% of COPD cases in the United States, with an estimated prevalence of 1 in 2000 to 5000 individuals. The disorder is inherited in an autosomal codominant fashion. The normal M allele is present in about 95% of the population, while the deficient Z allele occurs in 1% to 2% and the S allele in 2% to 3%. Severe deficiency most often occurs in individuals with the ZZ genotype, while those with SZ or MZ genotypes may have partial deficiency, with increased risk of lung disease—particularly in smokers. Approximately 1 in 10 individuals of European descent carries at least one abnormal allele.
Clinical manifestations vary depending on genotype and environmental exposures. The lungs are most commonly affected, with patients developing early-onset, lower-lobe–predominant panlobular emphysema, often before age 45 and sometimes in the absence of smoking. Symptoms resemble typical COPD and include progressive dyspnea, chronic cough, and sputum production. Bronchiectasis may also be present. Smoking significantly accelerates lung damage and worsens prognosis. Liver involvement may present as neonatal cholestasis, chronic hepatitis, cirrhosis, or hepatocellular carcinoma in both children and adults. A rare dermatologic manifestation is panniculitis, characterized by painful, inflammatory subcutaneous nodules caused by unopposed proteolysis in the skin.
The pathophysiology of AATD involves loss of antiprotease protection in the lungs and toxic accumulation of mutant AAT protein in hepatocytes. In the lungs, reduced AAT levels fail to adequately inhibit neutrophil elastase, leading to destruction of alveolar elastin and development of emphysema. In the liver, disease results not from deficiency but from intracellular retention of misfolded Z-AAT, which triggers hepatocellular injury, inflammation, and fibrosis. Not all individuals with AAT deficiency develop clinical disease, but smoking is the strongest modifiable risk factor for lung involvement.
Diagnosis should be suspected in patients with early-onset COPD, emphysema without typical risk factors, or basilar-predominant emphysema on imaging. Unexplained liver disease, panniculitis, bronchiectasis, poorly responsive asthma, or c-ANCA–associated vasculitis should also prompt evaluation. Initial testing includes measurement of serum alpha-1-antitrypsin levels, followed by genotyping to identify specific alleles. Pulmonary function testing typically shows airflow obstruction consistent with COPD. Imaging with chest radiography or high-resolution computed tomography often demonstrates lower-lobe–predominant emphysema and may reveal bronchiectasis.
Management begins with nonpharmacologic interventions, most importantly complete avoidance of smoking, which dramatically reduces the risk and progression of lung disease. Patients should also avoid occupational and environmental exposures that damage the lungs and receive routine vaccinations, including influenza, pneumococcal, pertussis, and SARS-CoV-2 vaccines. Acute COPD exacerbations are treated similarly to those in patients without AATD.
For chronic management, the therapeutic goal is to raise serum AAT levels above the protective threshold of approximately 50 mg/dL. Currently, the only FDA-approved disease-specific therapy is intravenous alpha-1-antitrypsin augmentation therapy, which uses pooled human AAT to slow progression of emphysema. This treatment requires lifelong administration, is costly, and does not reverse established lung damage nor improve liver disease. Patients with end-stage lung or liver disease may be candidates for organ transplantation, which can be life-saving and curative for the affected organ.
Prognosis depends on genotype, degree of deficiency, and environmental factors. Among patients with severe AATD, respiratory failure is the leading cause of death, followed by cirrhosis and liver-related complications. Early diagnosis, smoking cessation, and appropriate specialty care significantly improve outcomes. Referral to clinicians experienced in managing AATD is recommended, including pulmonology, hepatology, and transplant centers when indicated.
Alpha-1-antitrypsin deficiency remains substantially underdiagnosed, and expert guidelines recommend testing all patients with COPD, emphysema, irreversible asthma, unexplained liver disease, bronchiectasis, or panniculitis, as well as first-degree relatives of affected individuals. Early recognition allows for risk reduction, appropriate monitoring, and timely intervention to prevent irreversible organ damage.
- Published on
KembaraXtra-Medicine – Anal Cancer
Anal cancer refers to malignant transformation of the mucosa within the anal canal and may be squamous, neuroendocrine, or adenocarcinoma in subtype. It is also known as anal carcinoma, cancer of the anal canal, or malignant neoplasm of anus. The ICD-10CM code listed is C21.1 (Malignant neoplasm of anal canal).
Anal cancer is uncommon, occurring at a rate of 1–2 new cases per 100,000 population, with a median age of 63 years; in HIV-infected patients, the median age is <50 years. in the united states, 2022 estimates projected 9440 new cases and 1670 deaths. worldwide, 2020 (globocan) 50,865 19,293 deaths from anal cancer. incidence has increased 2%–3% annually over last 3 decades u.s., including young black men older women. there also been an increase locally advanced (node-positive) distant-disease cases, along with mortality elderly patients.< />pan>
The rise in incidence has been noted alongside the HIV epidemic and increased rates of sexually transmitted diseases. Risk factors include HIV infection (and unlike other HIV-associated malignancies, anal cancer incidence has not decreased in the era of highly active antiretroviral therapy), human papillomavirus (HPV) infection, cigarette smoking, and sexual practice risks such as men who have sex with men (MSM), women with >10 partners, and a history of anal intercourse. Additional risks include prior sexually transmitted diseases, genital warts, prior cervical cancer, and chronic immunosuppression.
Clinical presentation is often related to tumor size and degree of infiltration. Anorectal bleeding is the most common symptom, and patients may also report anorectal pain and fullness, as well as bowel habit changes including thin-caliber stools and a sense of incomplete evacuation. However, 20%–25% of patients may be asymptomatic. Local examination may reveal skin lesions, plaques, tumors, and a background of warts. Digital rectal examination assesses sphincter function, tumor location and size, tumor extent, and possible involvement of adjacent organs (e.g., vagina, prostate, rectum). At diagnosis, most cases are localized (85%), while the remainder are advanced or metastatic; inguinal adenopathy may be present in advanced disease.
Anal cancer development is strongly linked to anogenital HPV infection, especially HPV-16 and HPV-18, which account for most cases. Most infected individuals remain asymptomatic, and only some develop dysplasia over time. HPV proteins E6 and E7 promote oncogenesis by preventing apoptosis, causing cell-cycle arrest, and contributing to genomic instability. Chronic immunosuppression (e.g., from autoimmune therapy or organ transplantation) increases genital warts and persistence of HPV infection, promoting anal intraepithelial neoplasia (AIN) and eventual cancer. In HIV infection, low CD4 counts are a risk factor for development and progression of AIN.
The differential diagnosis includes anal fissures and fistulas, anal ulcers, anorectal abscess, chancroid, genital warts, and hemorrhoids.
Workup begins with careful local assessment: local examination followed by anoscopy/proctoscopy and colonoscopy to evaluate tumor extent. Imaging includes CT scans of the chest, abdomen, and pelvis to assess nodal and distant disease; pelvic MRI for tumor detail, sphincter involvement, and mesorectal nodal evaluation; and PET scans to detect nodal involvement and to help monitor response to therapy. Biopsy of the anal lesion is required to confirm diagnosis and cancer type, and inguinal nodal biopsy may be necessary to determine metastatic involvement. Recommended diagnostic evaluation includes digital rectal examination with tumor characterization, inguinal lymph node examination with biopsy or fine-needle aspiration if suspicious, anoscopy with biopsy, and in females a gynecologic examination including cervical cancer screening. Additional evaluation includes diagnostic PET-CT of chest/abdomen/pelvis (or pelvic MRI), CBC with serum chemistries, and HIV testing with CD4 levels in patients with risk factors. Laboratory tests include CBC, a complete metabolic panel, and HIV testing.
Staging uses TNM descriptors. T categories include Tx (cannot be assessed), T0 (no evidence), Tis (carcinoma in situ--Bowen disease/HSIL/AIN II-III), T1 (≤2 cm), T2 (>2 cm to ≤5 cm), T3 (>5 cm), and T4 (any size invading adjacent organ[s]); invasion of the rectal wall, perirectal skin, subcutaneous tissue, or sphincter muscles is not classified as T4. N categories include Nx (cannot be assessed), N0 (no regional metastasis), N1 (perirectal nodes), N2 (unilateral internal iliac and/or inguinal nodes), and N3 (perirectal and inguinal nodes and/or bilateral internal iliac and/or inguinal nodes). M categories are M0 (no distant metastasis) and M1 (distant metastasis). Stage groupings are: Stage 0 (Tis N0 M0), Stage I (T1 N0 M0), Stage II (T2–T3 N0 M0), Stage IIIA (T1–T3 N1 M0 or T4 N0 M0), Stage IIIB (T4 N1 M0 or any T with N2/N3 M0), and Stage IV (any T, any N, M1).
For most anal cancers, the mainstay of therapy is nonsurgical, using radiotherapy concurrent with systemic chemotherapy. Early small tumors (T1N0)—especially on the anal margin—may be treated with local surgical resection with wide margins. In some patients, a temporary colostomy may be needed to facilitate chemoradiotherapy. Abdominoperineal resection (APR) is generally reserved as salvage for persistent disease after definitive chemoradiotherapy or for locoregional recurrence.
Historically, APR achieved surgical cures in 25%–75%, but had up to a 35% locoregional relapse rate, especially with nodal involvement. Current standard care is mitomycin plus infusional 5-fluorouracil given concurrently with pelvic radiotherapy over about 5 weeks (CRT). If response is incomplete and biopsies remain positive, options include a radiotherapy boost or salvage APR. Combined-modality CRT is superior to radiotherapy alone and improves locoregional control, progression-free survival, overall survival, and colostomy-free survival. Major toxicities include myelosuppression, infections, dermatologic toxicity, and GI toxicity. Current clinical trials are studying radiotherapy de-escalation within CRT to reduce toxicity and improve tolerability and compliance. Locoregional recurrence occurs in about 10%–30%, and 5-year survival after salvage APR is about 40%–60%.
For distant metastatic or nonsurgical advanced disease, combination chemotherapy is preferred. Triplet regimens such as docetaxel/cisplatin/5-fluorouracil (DCF) may be used in fit patients, with >80% response rates and ~25% 5-year survival. Doublets such as CF (cisplatin/5-FU) or CP (carboplatin/paclitaxel) have response rates around 60% and median overall survival ~2 years; due to favorable toxicity, CP is preferred. In chemotherapy-refractory advanced disease, options include immune checkpoint inhibitors (nivolumab, pembrolizumab, avelumab, atezolizumab), and cetuximab (anti-EGFR) may be used palliatively.
Long-term care may include colostomy care and attention to nutritional requirements. Ongoing regular follow-up and examination are recommended to detect locoregional or distant recurrence. Referral is typically made to surgical oncology, radiation oncology, and medical oncology.
No formal screening guideline exists, but high-risk individuals (e.g., chronic immunosuppression, HIV, MSM) should be considered for routine local exam with anoscopy every 4–6 months plus annual anal cytology. Prevention is expected to be influenced by HPV vaccination. Gardasil 9 protects against nine HPV subtypes. Recommendations include vaccination for all children ages 11–12, girls/women ages 13–26, boys/men ages 13–21, and high-risk men ages 22–26, with an expanded indication allowing ages 27–45 to receive catch-up vaccination. In a randomized trial of 4459 participants with biopsy-proven HSIL, active treatment (office-based ablation, ablation/excision under anesthesia, or topical fluorouracil or imiquimod) continued until HSIL resolved, with high-resolution anoscopy at least every 6 months and biopsies per protocol. Over a median follow-up of 25.8 months, progression to anal cancer was 57% lower in the treatment group than in the active-monitoring group.
- Published on
KembaraXtra-Medicine – Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal degenerative neuromuscular condition of undetermined etiology that affects the corticospinal tracts and anterior horn cells, resulting in dysfunction of both upper motor neurons (UMNs) and lower motor neurons (LMNs). Synonyms include Lou Gehrig disease, ALS, and motor neuron disease. The ICD-10CM code is G12.21 (Amyotrophic lateral sclerosis).
ALS incidence is about two new cases per 100,000 persons per year. Onset is usually between 50 and 70 years, and the male-to-female ratio is 1.8:1. The estimated prevalence is 5.2 per 100,000 population.
Clinical presentation typically includes a combination of LMN signs—weakness, hypotonia, muscle wasting, fasciculations, and hyporeflexia or areflexia—and UMN signs—loss of fine motor dexterity, spasticity, extensor plantar responses, hyperreflexia, and clonus. Extraocular movements, sensation, and bowel and bladder function are typically preserved. Patients may develop dysarthria, dysphagia, pseudobulbar affect, and frontal lobe dysfunction. Respiratory insufficiency progresses to respiratory failure and death, typically late in the disease. Concomitant frontotemporal dementia occurs in about 15%, and executive dysfunction occurs in another 50%. Pseudobulbar affect (inappropriate crying or laughing not triggered by typical emotional cues) is common and treatable.
ALS commonly manifests in one of three onset patterns. Limb onset accounts for 75%–80% of cases and presents with painless muscle weakness, clumsiness (dropping things, stumbling, falling), impaired fine motor skills (e.g., writing), limb stiffness, gait disturbances, and wristdrop or footdrop. Bulbar onset accounts for 20%–25% and presents with dysarthria or voice change, pseudobulbar affect, dysphagia and/or weight loss, drooling, and choking during swallowing. Respiratory onset occurs in <3% and presents with dyspnea on exertion or at rest, orthopnea, daytime sleepiness, difficulty sleeping, other symptoms of respiratory compromise. als makes up about 90% adult-onset motor neuron diseases; disease presentations include progressive muscular atrophy, primary lateral sclerosis, bulbar palsy, pseudobulbar als-parkinsonism-dementia complex.< />pan>
Regarding etiology and classification, 90% of cases are sporadic and 10% are familial. Known genetic mutations include C9orf72 hexanucleotide repeat expansion (responsible for ~40% of familial ALS among those of European origin and nearly 10% of sporadic ALS, and virtually all ALS cases associated with frontotemporal dementia), SOD1 (copper-zinc superoxide dismutase) mutations (~12% of familial cases), TAR DNA-binding protein mutations (~4% of familial cases), and FUS (~4% of familial cases, rarely associated with frontotemporal dementia), among many others. Risk is increased in Whites, non-Hispanics, age >60 years, family history of ALS, and prior exposure to heavy metals, pesticides, or BMAA. A practical classification includes sporadic/acquired ALS variants (classic spinal-onset, Mills hemiplegic variant, pseudoneuritic, flail-arm, monomelic, UMN onset, LMN onset, bulbar onset, dyspnea onset, progressive muscular atrophy, primary lateral sclerosis, progressive bulbar palsy, Western Pacific ALS) and multiple familial ALS subtypes (ALS1 through ALS25 and additional rare-mutation forms). An FTD-ALS overlap is also recognized (e.g., ALS-FTD associated with C9orf72; and FTD with some ALS features associated with tau and progranulin genes on chromosome 17).
The differential diagnosis includes multifocal motor neuropathy with conduction block; cervical spondylotic myelopathy with polyradiculopathy; spinal stenosis with lumbosacral nerve root compression; chronic inflammatory demyelinating polyneuropathy with CNS lesions; syringomyelia; syringobulbia; foramen magnum tumor; meningeal carcinomatosis; spinal muscular atrophy; polyglucosan body disease; bulbospinal muscular atrophy (Kennedy disease); monomelic amyotrophy; Lyme disease; and ALS-like syndromes reported with lead intoxication, HIV, hyperparathyroidism, hyperthyroidism, lymphoma, and vitamin B12 deficiency.
Diagnosis is based on clinical findings, electromyography results, and exclusion of alternative causes. Workup includes MRI of brain and spine to exclude mimics; electromyography and nerve conduction studies following Revised El Escorial criteria; assessment of respiratory function (forced vital capacity [FVC], negative inspiratory force); assessment of swallowing and nutritional status; and neuropsychologic testing if executive dysfunction or FTD is a concern. The Revised El Escorial criteria require evidence of LMN degeneration (clinical, electrophysiologic, or neuropathologic), evidence of UMN degeneration (clinical), and progressive spread of symptoms/signs within or between regions, together with absence of electrophysiologic/pathologic evidence of another disease explaining UMN/LMN degeneration and absence of neuroimaging evidence of another explanatory disease process. Levels of certainty include Definite ALS (UMN and LMN signs in three regions), Probable ALS (UMN and LMN signs in two regions with UMN signs rostral to LMN signs), Probable ALS—Laboratory Supported (UMN signs in one or more regions with LMN signs by EMG in at least two regions), and Possible ALS (UMN and LMN signs in one region together, or UMN signs in two or more regions, or UMN and LMN signs in two regions without UMN signs rostral to LMN signs).
Laboratory tests that may be considered include vitamin B12, thyroid function, parathyroid hormone, and HIV, plus serum protein electrophoresis with immunofixation. In pure LMN syndromes, consider DNA studies for spinal muscular atrophy, bulbospinal atrophy (Kennedy disease), and hexosaminidase levels (late-onset Tay-Sachs). A 24-hour urine heavy metal screen may be done if indicated. In familial ALS, genetic studies should be performed with appropriate genetic counseling. Imaging is guided by clinical scenario; MRI brain and spinal cord help exclude structural mimics, and a modified barium swallow evaluates aspiration risk.
Treatment includes symptomatic management plus disease-modifying therapy that slows progression in some patients. Symptomatic treatment options span multiple domains: fatigue (pyridostigmine bromide, antidepressants, methylphenidate, amantadine, modafinil; energy conservation, work modification, sleep study with BiPAP if abnormal), spasticity (baclofen, tizanidine, dantrolene sodium, diazepam; physical therapy, range-of-motion exercises, botulinum toxin), jaw clenching (benzodiazepines, botulinum toxin into masseters), cramps (quinine sulfate, baclofen, vitamin E, clonazepam; massage, physical therapy), fasciculations (carbamazepine and reassurance), sialorrhea (hyoscyamine sulfate, diphenhydramine, scopolamine patch, glycopyrrolate, atropine, TCAs; suction machine, botulinum toxin into salivary glands, parotid radiation therapy, steam inhalation, nebulization, dark grape juice), pseudobulbar laughing/crying (TCAs, SSRIs, L-dopa/carbidopa, lithium, mirtazapine, venlafaxine, quinidine/dextromethorphan), thick phlegm (guaifenesin, nebulized N-acetylcysteine, nebulized saline, propranolol; insufflation-exsufflation, high-flow chest wall oscillation therapy, cool mist humidifier, rehydration, pineapple/papaya juice, reduced dairy/caffeine/alcohol), aspiration (cisapride and modified food consistency; in severe cases tracheostomy or modified laryngectomy with tracheal diversion), joint pains (anti-inflammatory drugs, analgesics, range-of-motion and heat), depression (TCAs; SSRIs/venlafaxine/mirtazapine/bupropion; counseling, support groups, psychiatry), insomnia (zolpidem tartrate, lorazepam, opioids, TCAs; pressure air pad/gel mattress; noninvasive ventilation where appropriate), laryngospasm (sublingual lorazepam), respiratory failure (bronchodilators, morphine sulfate; hospital bed, nocturnal noninvasive ventilator, IPPB), and constipation (increase oral fluids, Metamucil, Dulcolax suppositories, lactulose/other laxatives, exercise, “power pudding” of prune juice/prunes/applesauce/bran).
Nonpharmacologic therapy is central. Noninvasive ventilation can improve quality of life and may increase tracheostomy-free survival in patients with respiratory difficulty (orthopnea or FVC ≤50% predicted). Percutaneous endoscopic gastrostomy (PEG) can improve nutrition, stabilize weight, and ease medication administration; some studies suggest it may prolong life by 1–4 months, especially when placed before FVC falls to ≤50% predicted. Supportive services include nutrition support, speech therapy, physical and occupational therapy, suction devices for sialorrhea, cough assist devices for ineffective cough and airway clearance, and computerized assistive communication devices. Early advance-care planning discussions should address living will, resuscitation orders, preferences regarding PEG and tracheostomy, and long-term care options, and patients should be encouraged to connect with local support groups.
Disease-modifying medications do not cure ALS but can slow progression in selected patients. Riluzole (glutamate antagonist) was the first FDA-approved medication shown to extend tracheostomy-free survival; typical dosing is 50 mg every 12 hours, taken at least 1 hour before or 2 hours after meals, and it prolongs survival by about 2–3 months; ALT monitoring is recommended monthly for the first 3 months, then every 3 months until completion of the first year, and periodically thereafter. Edaravone (FDA approved 2017) slowed physical decline by 33% versus placebo in a 6-month phase III trial; it is given IV with an initial cycle of daily infusions for 14 days followed by 14 days off, then subsequent cycles of 10 infusions over 14 days followed by 14 days off; cost and insurance coverage can be limiting. Relyvrio (sodium phenylbutyrate/taurursodiol) is an FDA-approved oral fixed-dose combination (approved 2022) for adults with ALS that helps slow progression; its exact mechanism is unknown, but it targets endoplasmic reticulum and mitochondria-dependent neuronal degeneration pathways, and is thought to reduce neuronal death and dysfunction.
Chronic management includes targeted symptom control such as treating sialorrhea with glycopyrrolate or amitriptyline (and considering propranolol or metoprolol if secretions are thick), using botulinum toxin if refractory; treating spasticity with baclofen, tizanidine, or clonazepam; and treating pseudobulbar affect with amitriptyline, sertraline, or dextromethorphan/quinine.
Disposition reflects the progressive nature of ALS: there is currently no cure, mean symptom duration is 3-5 years, and about 20% of patients survive more than 5 years. Referral to a neurologist experienced in neuromuscular disease is recommended to confirm diagnosis, and multidisciplinary ALS clinics may improve survival. Gastroenterology referral for PEG placement is recommended while FVC remains >50% to reduce procedural morbidity, and pulmonology referral is appropriate for noninvasive ventilation such as BiPAP.
Pearls include the importance of patient-physician communication at diagnosis and throughout care, and the value of a multidisciplinary supportive approach to improve daily functioning and independence. Related content includes patient information resources on ALS.
